Sponsored content

Collaborative Research and Licensing Opportunity: Live Attenuated Zika Virus Vaccine

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have new technology based on live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses.

Upvote 1 Comment

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have new technology based on live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses.The chimeric Zika viruses of the technology include a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3' untranslated region from a second flavivirus.  The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure also describes methods of inducing immune responses, as well as preventing ZIKV and another flavivirus, e.g., dengue virus.

Such a chimeric vaccine candidate may induce a humoral (antibody) and T-cell response to ZIKV, while the nonstructural proteins of dengue virus will likely induce a T-cell response. The dengue platform also contains a deletion in the TL2 stem-loop structure of the 3' untranslated region (UTR), called D30 and D30/31 attenuating mutations. The D30 deletion has proven to be one of the defining characteristics of the successful one dose dengue vaccine, which is currently in a large scale (17,000 patient) clinical trial in Brazil. 

Potential Commercial Applications: 

  • Diagnostics
  • Vaccines

Competitive Advantages: 

  • One-dose vaccine
  • Ease of manufacture
  • Can be included in multivalent flavivirus vaccines

Development Stage: 

·         In vivo data available (animal)

Inventors:  S. Whitehead (NIAID), S. Woodson (NIAID), A. Pletnev (NIAID), K. Tsetsarkin (NIAID), A. Durbin (Johns Hopkins University)

Intellectual Property:  HHS Reference No. E-118-2016/0, U.S. Provisional Patent Application Number 62/307,170, filed March 11, 2016, PCT Patent Application TBA filed March 11, 2017.

Licensing and Collaborative Research Opportunity:The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in licensing or collaborative research to further co-develop this technology. For opportunities, please contact Peter Soukas, J.D., 301-594-8730; peter.soukas@nih.gov.


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
20 Contributions
12 Followers
1 Following

Please sign in or register for FREE to comment